GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvectis Pharma Inc (NAS:NVCT) » Definitions » Cash Ratio

Nuvectis Pharma (Nuvectis Pharma) Cash Ratio : 3.42 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Nuvectis Pharma Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Nuvectis Pharma's Cash Ratio for the quarter that ended in Mar. 2024 was 3.42.

Nuvectis Pharma has a Cash Ratio of 3.42. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Nuvectis Pharma's Cash Ratio or its related term are showing as below:

NVCT' s Cash Ratio Range Over the Past 10 Years
Min: 2.37   Med: 4.46   Max: 18.54
Current: 3.42

During the past 4 years, Nuvectis Pharma's highest Cash Ratio was 18.54. The lowest was 2.37. And the median was 4.46.

NVCT's Cash Ratio is ranked better than
52.75% of 1475 companies
in the Biotechnology industry
Industry Median: 3.03 vs NVCT: 3.42

Nuvectis Pharma Cash Ratio Historical Data

The historical data trend for Nuvectis Pharma's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvectis Pharma Cash Ratio Chart

Nuvectis Pharma Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash Ratio
- 2.37 3.23 2.74

Nuvectis Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.93 5.34 3.96 2.74 3.42

Competitive Comparison of Nuvectis Pharma's Cash Ratio

For the Biotechnology subindustry, Nuvectis Pharma's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nuvectis Pharma's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvectis Pharma's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Nuvectis Pharma's Cash Ratio falls into.



Nuvectis Pharma Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Nuvectis Pharma's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=19.126/6.984
=2.74

Nuvectis Pharma's Cash Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash Ratio (Q: Mar. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=19.464/5.692
=3.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nuvectis Pharma  (NAS:NVCT) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Nuvectis Pharma Cash Ratio Related Terms

Thank you for viewing the detailed overview of Nuvectis Pharma's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuvectis Pharma (Nuvectis Pharma) Business Description

Traded in Other Exchanges
N/A
Address
1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, NJ, USA, 07024
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. Its pipeline products include NXP800, NXP900.
Executives
Ron Bentsur director, officer: Chairman & CEO 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Marlio Charles Mosseri 10 percent owner 27 RIPPLEVALE GROVE, LONDON X0 N1 1HS
Enrique Poradosu officer: Chief Science and Business Off C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, FORT LEE NJ 07024
Shay Shemesh officer: Chief Development Officer C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Michael J. Carson officer: Vice President, Finance C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Kenneth Hoberman director 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Oliviero James F Iii director C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Uri Ben-or officer: Int. Principal Financial Off. C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Matthew L. Kaplan director C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024

Nuvectis Pharma (Nuvectis Pharma) Headlines

From GuruFocus

Is Nuvectis Pharma Inc Undervalued Following the Latest Insider Buy?

By GuruFocus Research GuruFocus Editor 09-06-2022

Is Nuvectis Pharma Inc Undervalued Following the Latest Insider Buy?

By GuruFocus Research GuruFocus Editor 05-19-2023